Company / Depreciation & Amortization
Arcadia Biosciences, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$58.0K
FY2025
5-year range
$58.0K / $929.0K
FY2021-FY2025
Trend
-47.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has declined for 3 consecutive years, from $929,000 in FY2022 to $58,000 in FY2025.
Based on SEC 10-K filings.
$58,000 in FY2025 with a 5-year CAGR of -21.5%.
Improved from $439,000 to $58,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -60.3%
- 5-Year CAGR
- -21.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s depreciation & amortization has declined for 3 consecutive years.
- 5-year CAGR of -21.5%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 47.7% year-over-year.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.0K | -47.7% |
| FY2024 | $111.0K | -74.7% |
| FY2023 | $439.0K | -52.7% |
| FY2022 | $929.0K | +47.0% |
| FY2021 | $632.0K | +225.8% |
| FY2020 | $194.0K | +26.0% |
| FY2019 | $154.0K | -44.8% |
| FY2018 | $279.0K | -8.2% |
| FY2017 | $304.0K | +3.4% |
| FY2016 | $294.0K | -17.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026